Business

CVS Expands Access to Lilly’s GLP-1 Medications

Updated 2026-05-28 19:20 UTC 1 source Positive

CVS will cover Lilly's new GLP-1 medications, Foundayo and Zepbound, potentially opening access for millions of Americans. This move aims to improve patient care and medication affordability.

Coverage timeline — 1 article

MarketWatch

Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

That means millions more Americans may get access to Lilly’s new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.

2026-05-28 19:08 UTC